Flexion Phase II data for FX005 gives clinical PoC in arthritis pain
This article was originally published in Scrip
Flexion Therapeutics reported topline data from a Phase II proof-of-concept study that showed that its lead anti-inflammatory drug candidate FX005 was well-tolerated, provided sustained pain relief and improved joint function for patients with moderate osteoarthritis in the knee.
You may also be interested in...
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.